

Chemical and Pharmaceutical Bulletin

Instructions for Authors

The journal Chemical and Pharmaceutical Bulletin aims to advance pharmaceutical sciences worldwide and will accept original, innovative submissions in English from both members and nonmembers of the Pharmaceutical Society of Japan. The submissions should be previously unpublished and not being considered for publication elsewhere. All listed authors must agree with the contents of the paper and give their consent for its submission.

Only manuscripts written in clear, concise English will be accepted for review. Authors who are not native English speakers should note that only manuscripts checked and edited by a native English speaker with sufficient scientific knowledge will be accepted. English judged to be inadequate by the Editorial Board will be edited at the authors' expense before publication.

I. TYPES OF MANUSCRIPT

The Journal publishes Reviews, Communications, Regular Articles, and Notes.

1. Reviews:

(1) Regular Reviews: Reviewing scientific discoveries including the recent results of the author(s).

(2) Invited Reviews: Submitted by invitation from the Editorial Board, and encompass recent important scientific discoveries.

2. Communications: Communications should contain new and important information that would be of interest to readers of the Journal, making urgent publication is desirable. An explanatory statement is required for urgent publication. In general, a Communication should not exceed 2000 words (approximately 4 printed pages).

3. Regular Articles: The manuscript being submitted must consist of original research performed by the authors and the research must include new information that is of significance.

4. Notes: Papers containing new facts and important data derived from incomplete or partial studies may be suitable as a Note. In general, a Note should not exceed 2000 words (approximately 4 printed pages).

II. MANUSCRIPT PREPARATION

1. Cover letter The cover letter should include information on the corresponding author (the corresponding author's name, affiliation and address, telephone/fax numbers, and e-mail address).

As for Communications, please indicate in the cover letter the reason why the manuscript should be treated as a Communication.

2. Manuscript The text, figures, and tables should be submitted as three separate files or one file. These are automatically incorporated into a single PDF that the system creates for review. Please use Times New Roman font in 12-point size for Word files. All files should have a page setup for A4-sized (210 mm wide × 297 mm high) paper when printed. Tables can be displayed horizontally if necessary.

(1) Title page The title page (page 1) should start with the journal name (*Chem. Pharm. Bull.*) and type of manuscript (Communication, Regular Article, etc.). This should be followed by the title, name(s) of the author(s), affiliation(s), and mailing address(es). Please indicate the corresponding author's e-mail address in the footnote. An asterisk (*) should be added to the right of the corresponding author's name. Use a dagger (†) to the right of a name to indicate that the present affiliation of an author is different to that of when the paper was written. In the footnotes, show the author's current affiliation and address.

(2) Summary and Keywords Page 2 should contain a summary no longer than 250 words as well as 3 to 6 descriptive keywords, listed in decreasing order of importance. The first 3 keywords must be independent, as they will be used in a keyword combination in the index (within 80 characters). Abbreviations should not be used as keywords.

(3) Main text The text, acknowledgments, conflict of interest, and references should be presented in this order.

3. Graphical Abstracts The graphical abstract, which authors must supply at the time the manuscript is first submitted, is presented in the Table of Contents so that readers can grasp the outline of the manuscript at a glance. Graphical abstracts should consist of carefully drawn figures (chemical structures, charts, graphs, images, or other informative illustrations) that show the most striking feature of the article in a pictorial form. Appropriate text may be included in the illustration. The illustration should be no larger than 100 mm wide × 40 mm high. The use of color to enhance the value and quality of the graphic is encouraged since they will be printed in color.

4. Supplementary materials If an article has some supplementary materials, the author(s) should state it between Conflict of Interest and References: "The online version of this article contains supplementary materials."

5. Additional information for review Other data necessary for review may be submitted as additional information. Additional information will not be published in the journal.

III. MANUSCRIPT FORM

1. Affiliations When there are two or more authors and they belong to more than one affiliation, the connection between each author and his or her affiliation should be indicated by italicized superscripts *a*, *b*, *c*... placed after each author's name and before each affiliation.

Examples for describing affiliations and mailing addresses:

^aDepartment of Molecular Biology, Graduate School of Pharmaceutical Sciences, Hokkaido University; Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan; ^bBiomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST); Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 350-8566, Japan; and ^cDepartment of Pharmaceutical Services, Hiroshima University Hospital; 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.

2. Abbreviations Abbreviations must be spelled out in full at their initial appearance each in the summary and the main text, followed by the abbreviation in parentheses. Thereafter, the abbreviation only may be used. Please limit to a minimum the use of abbreviations in the title. However, the following need not be defined: ADP (adenosine 5'-diphosphate), AIDS (acquired immunodeficiency)

ciency syndrome), AMP (adenosine 5'-monophosphate or adenylic acid), ANOVA (analysis of variance), ATP (adenosine 5'-triphosphate), cAMP (adenosine 3',5'-cyclic monophosphate), cDNA (complementary DNA), CoA (coenzyme A), CYP (cytochrome P450), DNA (deoxyribonucleic acid), ED₅₀ (50% effective dose), ESR (electron spin resonance), FAB-MS (fast atom bombardment mass spectrometry), FAD (flavin adenine dinucleotide), GC-MS (gas chromatography-mass spectrometry), GLC (gas-liquid chromatography), GMP (guanosine 5'-monophosphate), HPLC (high-performance liquid chromatography, high-pressure liquid chromatography), IC₅₀ (inhibitory concentration, 50%), IR (infrared), LC (liquid chromatography), LC/MS (liquid chromatography/mass spectrometry), LD₅₀ (50% lethal dose), mRNA (messenger RNA), MS (mass spectrum), NMR (nuclear magnetic resonance), OTC (over the counter), PCR (polymerase chain reaction), QOL (quality of life), RNA (ribonucleic acid), RT-PCR (reverse transcription polymerase chain reaction), TLC (thin-layer chromatography), tRNA (transfer RNA), UV (ultraviolet), WHO (World Health Organization)

3. Units The following units should be used: length (m, cm, mm, μ m, nm, Å), mass (kg, g, mg, μ g, ng, pg, mol, mmol, μ mol), volume (L, mL, μ L), time (s, min, h, d), temperature ($^{\circ}$ C, K), radiation (Bq, dpm, Gy, Sv), and concentration (M, mM, mol/L, mmol/L, mg/mL, μ g/mL, %, % (v/v), % (w/v), ppm, ppb)

4. Spectral and Elemental Analysis Data Please report spectral and elemental analysis data in the following format. ¹H-NMR (CDCl₃) δ : 1.25 (3H, d, J = 7.0 Hz), 3.55 (1H, q, J = 7.0 Hz), 6.70 (1H, m). ¹³C-NMR (CDCl₃) δ : 20.9 (q), 71.5 (d), 169.9 (s). IR (KBr) cm⁻¹: 1720, 1050, 910. UV λ_{max} (EtOH) nm (ϵ): 241 (10860), 288 (9380). UV λ_{max} (H₂O) nm (log ϵ): 280 (3.25). FAB-MS m/z : 332.1258 (Calcd for C₁₈H₂₀O₆: 332.1259). MS m/z : 332 (M⁺), 180, 168. [α]_D²³ -74.5 (c = 1.0, MeOH). Anal. Calcd for C₁₉H₂₁NO₃: C, 73.29; H, 6.80; N, 4.50. Found: C, 73.30; H, 6.88; N, 4.65.

5. Nomenclature The nomenclature used for chemical compounds shall be in accordance with the nomenclature rules formulated by IUPAC. Alternatively, naming may conform to the nomenclature in the index of *Chemical Abstracts* or the Ring Index.

6. References and Notes "References" include articles published in journals, books, on the Internet, and others (technical reports, patents, lectures, *etc.*). References other than those indicated above should be described in the text. References should be numbered consecutively according to the order of citation in the text (one Arabic number should be assigned to each reference or note). An Arabic number followed by a right-hand half-parenthesis should be placed after the last relevant word in the sentence, outside the punctuation mark if any, and all references should be listed in numerical order at the end of the text in the section entitled References and Notes. Journal abbreviations should conform to those listed by *Chemical Abstracts* (cf. The ACS Style Guide. A Manual for Authors and Editors).

Examples of references are as follows:

- 1) Roques B. P., Florentin D., Callanquin M., *J. Heterocycl. Chem.*, **12**, 195–196 (1975).
- 2) Cruickshank R., Duguid I. P., Marmion B. P., Swain R. H. A., "Medical Microbiology," 12th ed., Vol. III, Churchill Livingstone, New York, 1975.
- 3) Szejtli J., "Cyclodextrin Technology," ed. by Davis J. E. D., Kluwer Academic, Dordrecht, 1988.
- 4) Tokuda H., Ichiishi E., Onozuka M., Yamaguchi S., "Biology of Nitric Oxide, Part 6," Vol. I, Chap. 2, ed. by Moncada S., Tada N., Maeda H., Portland Press, London, 1998, pp. 185–186.
- 5) Brunner A., Greune H., U. S. Patent 1910462 (1993) [*Chem. Abstr.*, **27**, 4092–4096 (1993)].
- 6) Based on a lecture presented at the 30th Symposium on Heterocyclic Chemistry, Tokyo University of Pharmacy & Life Science, Hachioji, on 25 November, 1999.
- 7) International Organization for Standardization. "How we develop standards." (<<https://www.iso.org/developing-standards.html>>), cited 5 September, 2018.

In the References section, include the last names and initials of the first and middle names for all authors.

For references appearing in the main text, the last names of the first 2 authors only should be written. For references with 3 or more authors, write the name of the first author followed by *et al.* (Example: Jones *et al.*).

IV. X-RAY CRYSTAL STRUCTURE ANALYSES

When structure determination by X-ray crystallographic analysis is a central theme of a paper, the data required for registration with the Cambridge Crystallographic Data Centre (CCDC) should be attached as supplementary material. Although this does not apply in cases where crystallographic analysis plays only a supplementary role, crystal data (unit cell parameters, space group, Z density) and R-factor should still be noted. Atomic coordinates will be printed when the structure is important. Bond lengths and angles, thermal parameters, and torsion angles will be printed when they are important for the issues addressed in the paper. When papers have been accepted, the authors are advised to register the data with CCDC.

V. NUCLEOTIDE SEQUENCES

Newly reported nucleotide sequences must be deposited in one of the data banks, (either DDBJ, GenBank, or EMBL) and an accession number must be obtained before the paper will be accepted by the Editorial Board. Access to the information in the database must be available at the time of publication. A footnote will be included in the paper indicating that such a deposit has been made.

VI. CONFLICT OF INTEREST

A conflict of interest (COI) exists when anyone has financial or personal relationships that could inappropriately influence (bias) a submitted manuscript. All authors are requested to disclose any financial relationship with any company or institution that might benefit from the publication of the manuscript.

Authors should consider as a guide for financial disclosures:

1. Research funding from a for-profit (commercial) organization
2. Consulting fee/honorarium
3. Patent royalties/licensing fees
4. Employment/leadership position/advisory role
5. Others (travel fees, gift, *etc.*)

This disclosure must be included in the text of the manuscript under the Conflict of Interest heading. If the authors have no conflict of interest, they must state as much, “The authors declare no conflict of interest.” And if they have some conflict of interest, they must state as much, for example: A (author name) received a research grant from O (entire company, institute or personal name); B received non-financial support from P; C serves as a consultant to Q; D received honoraria for writing promotional material for R; E has a patent JP Patent 12345 licensed to S; F is President of T; G has been reimbursed by U for attending conferences; H and I are employees of X; J has no conflict of interest.

VII. ETHICS

1. For manuscripts dealing with scientific investigations involving human subjects and/or human tissues, the experiments should be performed in accordance with the ethical principles for medical research outlined in the Declaration of Helsinki 1964 as modified by subsequent revisions (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>).

Only studies that have been performed after receiving approval from the appropriate ethics committee of an institution will be accepted for publication. Finally, please clearly state in the manuscript that the study was performed according to institutional guidelines and attach to the cover letter a scanned certificate from the ethics committee.

2. Manuscripts describing animal experiments should be conducted in accordance with the experimental animal guidelines of the institution as well as the appropriate government guidelines, such as those published by the Japanese Ministry of Education, Culture, Sports, Science and Technology. Only manuscripts of experiments conducted in accordance with the appropriate guidelines will be eligible for publication. Finally, please state clearly within the manuscript which guidelines were followed and that the study was indeed conducted in accordance with the guidelines.

VIII. REFEREES

1. With the exception of Invited Reviews, manuscripts will be reviewed by two or more referees, whose opinions will form the basis of the final decision by the editor.

2. Please submit the revised manuscript no later than two months from the date of notification of manuscript revision by the editor. A manuscript that is not revised within two months may be rejected.

IX. CHARGES

1. Submission Fee: The one-time fee of 3000 Japanese yen/manuscript, payable by credit card, will be applied to new submissions only.

2. Page Charge: 5000 Japanese yen per printed page.

3. Reprint Charges (Japanese yen)

Number of Pages \ Number of Reprints	1~2	3~4	5~6	7~8	9~10	11 or more
50	¥8000	¥9000	¥10000	¥11000	¥12000	¥13000
100	¥14400	¥16200	¥18000	¥19800	¥21600	¥23400
150	¥19200	¥21600	¥24000	¥26400	¥28800	¥31200
200	¥22400	¥25200	¥28000	¥30800	¥33600	¥36400
250 or more	¥110 each	¥120 each	¥130 each	¥150 each	¥160 each	¥180 each

· Postage included.

· Color printing carries an extra surcharge of ¥80 per page.

· Reprints only available in multiples of 50. · Cover charge: ¥30 each.

4. Color figures: 60000 Japanese yen per printed page or 4000 Japanese yen per figure only online.

5. Actual cost for English revision and editing.

The charges for page, reprint, and color figure(s) do not include consumption tax.

The Journal reserves the right to modify the charges without prior notification.

X. OTHER IMPORTANT POINTS

1. In general, after a paper has been reviewed, no authors may be added or deleted from the paper, and the order of the names of the authors cannot be changed.

2. The authors are given an opportunity to proofread the galley of an accepted manuscript. No additions and revisions are allowed other than the correction of typographical errors.

3. The copyrights of all manuscripts published in the Chemical and Pharmaceutical Bulletin belong to the Pharmaceutical Society of Japan. The author must submit a Copyright Transfer form to the Pharmaceutical Society of Japan.